Moderní trendy ve farmakologické léčbě srdečního selhání
| Title in English | Modern trends in pharmacological treatment heart failure |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Klinická farmakologie a farmacie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.solen.cz/artkey/lek-202103-0015_moderni_trendy_ve_farmakologicke_lecbe_srdecniho_selhani.php?back=%2Fsearch.php%3Fquery%3Dfarmakoterapie%2Bv%2Bt%25C4%259Bhotenstv%25C3%25AD%26sfrom%3D30%26spage%3D30 |
| Doi | http://dx.doi.org/10.36290/far.2021.009 |
| Keywords | heart failure; pharmacotherapy; ACE inhibitors; sartans; betablockers; diuretics; digoxin; sacubitril/valsartan; inhibitors SGLT2-gliflozins; omecamtiv mecarbil; vericiguat; new drugs |
| Description | ACE inhibitors and betablockers are the cornerstone of the treatment of heart failure, MRA should be added. Angiotensin receptor blockers (ARB) are indicated in the case of ACE inhibitors intolerance. Renin angiotensin blockers and betablockers should be given in maximal tolerated doses. Diuretics are given to the symptoms relieve – dyspnoe or oedema. Digoxin is indicated in selected patients. There are 3 new promising groups of drugs: 1. Angiotensin Receptor-Neprilysin Inhibitor – ARNI – Sacubitril/Valsartan can replace the ACE-I?according to the results of the PARADIGM-HF trial. 2. Sodium–glucose co-transporter-2 (SGLT2) inhibitors in patients with diabetes mellitus/prediabetes. 3. A?hughe clinical research is done with omecamtiv mecarbil, vericiguat and other perspective drugs. |